Market Cap | 154.98M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -29.47M | Forward P/E | -0.02 | EPS next Y | - | 50D Avg Chg | - |
Sales | 10M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 25.00% |
Dividend | N/A | Price/Book | 2.50 | EPS next 5Y | - | 52W High Chg | -18.00% |
Recommedations | 1.50 | Quick Ratio | 6.18 | Shares Outstanding | 140.24M | 52W Low Chg | 151.00% |
Insider Own | 0.51% | ROA | -18.98% | Shares Float | 335.29M | Beta | - |
Inst Own | 61.41% | ROE | -45.56% | Shares Shorted/Prior | 2.19M/2.78M | Price | 1.24 |
Gross Margin | 74.26% | Profit Margin | -294.66% | Avg. Volume | 1,930,119 | Target Price | 4.94 |
Oper. Margin | -1,576.50% | Earnings Date | Mar 29 | Volume | 485,900 | Change | -8.15% |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Needham | Buy | Mar 28, 24 |
Cantor Fitzgerald | Overweight | Mar 22, 24 |
Cantor Fitzgerald | Overweight | Sep 8, 23 |
Needham | Buy | Sep 8, 23 |
Needham | Buy | Aug 23, 23 |
Needham | Buy | Jun 6, 23 |
Needham | Buy | May 26, 23 |
Needham | Buy | Apr 21, 23 |
Needham | Buy | Mar 30, 23 |